首页/数据集/Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia

Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia

NIAID Data Ecosystem2026-05-02 收录

数据链接：

https://figshare.com/articles/dataset/Supplementary_Data_from_Preclinical_Development_of_Tuspetinib_for_the_Treatment_of_Acute_Myeloid_Leukemia/28193221 数据链接链接失效反馈

官方服务：

资源简介：

Information on antibody RRID and Other catalog numbers

应用场景：

创建时间：

2025-01-13

急性髓系白血病药物研究

c-Myc信号通路

The treatment of acute myeloid leukemia (AML) continues to be challenged by relapse and resistance, necessitating the development of novel therapeutic strategies. Toosendanin (TSN), a natural product

NIAID Data Ecosystem70

Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia

急性髓系白血病药物研究

双靶点抑制剂

Nowadays, the simultaneous inhibition of two or more pathways plays an increasingly important role in cancer treatment due to the complex and diverse pathogenesis of cancer, and the combination of the

NIAID Data Ecosystem50

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia (RNA-Seq II). Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in Acute Myeloid Leukemia (RNA-Seq II)

急性髓系白血病药物研究

转录组学分析

Purpose: Compare transcriptional changes between drug treated (gilteritinib, TP-0903) and vehicle in acute myeloid leukemia xenografts. Methods: FLT3-ITD+ MOLM13-Luc+ AML cells were xenografted into N

NIAID Data Ecosystem30

Novel IDH1 Mutant Inhibitors for Treatment of Acute Myeloid Leukemia

IDH1突变抑制剂

急性髓系白血病药物研究

This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series

NIAID Data Ecosystem60

RNA-seq of MV-4-11 or THP-1 cells treated with LSD1 inhibitor INCB059872. RNA-seq of MV-4-11 or THP-1 cells treated with LSD1 inhibitor INCB059872

LSD1抑制剂转录组

急性髓系白血病药物研究

INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. LSD1 inhibition can induce differentiation of

NIAID Data Ecosystem30

Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia

资源简介：

相关数据集